Cargando…

Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases

The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiaopeng, Wang, Xisheng, Xue, Xingkui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321265/
https://www.ncbi.nlm.nih.gov/pubmed/35889373
http://dx.doi.org/10.3390/molecules27144498
_version_ 1784756000060866560
author Hu, Xiaopeng
Wang, Xisheng
Xue, Xingkui
author_facet Hu, Xiaopeng
Wang, Xisheng
Xue, Xingkui
author_sort Hu, Xiaopeng
collection PubMed
description The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD26 also plays an integral role in the immune system, particularly in T cell activation. CD26 is extensively expressed in immune cells, such as T cells, B cells, NK cells, dendritic cells, and macrophages. The enzymatic activity of CD26 cleaves and regulates numerous chomokines and cytokines. CD26 inhibitors have been widely used for the treatment of diabetes mellitus, while it is still under investigation as a therapy for immune-mediated diseases. In addition, CD26’s involvement in cancer immunology was also described. The review aims to summarize the therapeutic effects of CD26 inhibitors on immune-mediated diseases, as well as the mechanisms that underpin them.
format Online
Article
Text
id pubmed-9321265
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93212652022-07-27 Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases Hu, Xiaopeng Wang, Xisheng Xue, Xingkui Molecules Review The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role in glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) and gastric inhibitory protein (GIP). A large number of studies demonstrate that CD26 also plays an integral role in the immune system, particularly in T cell activation. CD26 is extensively expressed in immune cells, such as T cells, B cells, NK cells, dendritic cells, and macrophages. The enzymatic activity of CD26 cleaves and regulates numerous chomokines and cytokines. CD26 inhibitors have been widely used for the treatment of diabetes mellitus, while it is still under investigation as a therapy for immune-mediated diseases. In addition, CD26’s involvement in cancer immunology was also described. The review aims to summarize the therapeutic effects of CD26 inhibitors on immune-mediated diseases, as well as the mechanisms that underpin them. MDPI 2022-07-14 /pmc/articles/PMC9321265/ /pubmed/35889373 http://dx.doi.org/10.3390/molecules27144498 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Hu, Xiaopeng
Wang, Xisheng
Xue, Xingkui
Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
title Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
title_full Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
title_fullStr Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
title_full_unstemmed Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
title_short Therapeutic Perspectives of CD26 Inhibitors in Imune-Mediated Diseases
title_sort therapeutic perspectives of cd26 inhibitors in imune-mediated diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321265/
https://www.ncbi.nlm.nih.gov/pubmed/35889373
http://dx.doi.org/10.3390/molecules27144498
work_keys_str_mv AT huxiaopeng therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases
AT wangxisheng therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases
AT xuexingkui therapeuticperspectivesofcd26inhibitorsinimunemediateddiseases